Which devices are suitable for FDA De Novo classification?
For manufacturers planning to introduce an innovative medical device to the United States, selecting the appropriate FDA pathway is a fundamental stage of product development and market-entry strategy. The U.S. Food and Drug Administration (FDA) developed De Novo classification for new device types without an appropriate legally marketed predicate whose risks can be managed through suitable regulatory controls. It enables innovative technologies to be placed in an appropriate risk class following evaluation of safety and effectiveness.
De Novo is generally considered for new low- or moderate-risk device types. Technological innovation alone does not establish eligibility. Intended use, available predicates, and foreseeable risks must be evaluated together. The purpose is to classify devices for which general controls, or general and special controls, provide reasonable assurance of safety and effectiveness.
Basic eligibility conditions for innovative devices
Eligibility depends on the device’s position within the existing classification system as well as its innovative features. The FDA examines whether the new type can be adequately controlled as low or moderate risk and whether substantial equivalence can be established using existing predicates.
Manufacturers must clearly explain intended use, technological characteristics, potential hazards, and risk controls. They should justify why the product represents a new device type within the regulatory framework, rather than merely a different design.
- New device type: Devices requiring new classification because substantial equivalence to an appropriate predicate cannot be demonstrated.
- Low or moderate risk: Device types whose foreseeable risks can be managed through appropriate controls.
- Defined intended use: Products with a clearly identified clinical or healthcare purpose.
- Safety and effectiveness evidence: Devices whose probable benefits, risks, and controls can be evaluated.
- Appropriate controls: Types for which general controls, or general and special controls, can provide reasonable assurance.
Can software-based and digital devices qualify?
Software devices, digital technologies offering new diagnostic or clinical assessment methods, and certain decision-support systems may qualify. However, healthcare use alone does not automatically make software a medical device or establish De Novo eligibility. The product must first be assessed against the FDA medical device definition.
Assessment should consider intended use, users, the clinical influence of outputs, and risks from incorrect results. A new algorithm or technology alone is insufficient. The manufacturer must demonstrate the absence of an appropriate predicate and the adequacy of applicable risk controls.
Diagnostic and patient-monitoring technologies
New diagnostic methods, health assessment technologies, and clinical monitoring systems may be considered. Review focuses on how information will be used and the potential patient-safety consequences of incorrect or incomplete results.
Technological differences do not mean that review considers technology alone. The product’s diagnostic or monitoring role, user interpretation, and mitigation methods must also be assessed. The clinical context should therefore be clearly defined.
When is De Novo unsuitable?
De Novo is not available for every innovative device. High-risk devices for which general or special controls cannot provide adequate assurance may require another pathway. Risk level and available classification options must be examined together.
If an appropriate predicate exists and substantial equivalence can be demonstrated, 510(k) may be more suitable. A different commercial name, additional features, or design changes do not automatically require De Novo.
What should be assessed before submission?
Manufacturers should define intended use, technological characteristics, and target users, then examine FDA classifications and marketing decisions for suitable predicates. This helps avoid selecting the wrong pathway.
Probable benefits, foreseeable risks, and controls should also be assessed systematically. Performance validation, usability assessment, and scientific evidence may be needed depending on the product. Eligibility should follow an integrated review of this information.
Why De Novo classification matters to manufacturers
De Novo enables new low- or moderate-risk device types without predicates to be classified within the U.S. system. A granted request may establish Class I or II status, authorize marketing, and create a classification that supports future device assessments.
Submission does not guarantee a grant or marketing authorization. Manufacturers must support benefits, risks, and control adequacy with evidence. De Novo is a risk-based classification process for eligible new device types, rather than an automatic advantage for every innovative product.
The fundamental difference between De Novo and 510(k)
FDA De Novo and 510(k) are separate market-entry pathways addressing different assessment needs. Their central distinction is whether a device can be evaluated against an appropriate legally marketed predicate. While 510(k) establishes substantial equivalence, De Novo provides risk-based classification of new device types without an appropriate predicate.
This distinction directly affects submission strategy, technical assessment, and required evidence. Safety and effectiveness matter in both, but their assessment foundations differ. Manufacturers researching what FDA approval means should distinguish clearance, De Novo classification, and PMA approval.
Substantial equivalence under 510(k)
The 510(k) process aims to demonstrate substantial equivalence to an appropriate legally marketed predicate. Manufacturers compare intended use and technological characteristics with those of the predicate.
Identical characteristics are not required. Technological differences may be acceptable if intended use is the same, no new safety or effectiveness questions arise, and scientific data supports the new device being as safe and effective as the predicate.
Risk-based classification under De Novo
De Novo evaluates new device types without appropriate predicates. Its purpose is to determine whether risks can be managed through regulatory controls rather than prove equivalence to an existing product. Class I or II classification may result.
Applicants explain intended use, technology, foreseeable risks, and controls. The FDA assesses whether general controls, or general and special controls, provide reasonable assurance. The scientific basis therefore concerns independent assessment of the new type’s benefits and risks.
How does predicate availability affect the pathway?
If a suitable predicate can be identified and equivalence supported, 510(k) may be appropriate. If intended use or technology leaves no suitable predicate, De Novo may be considered.
A prior 510(k) is not always required. Manufacturers may submit directly or consider De Novo after certain not-substantially-equivalent decisions. Failure caused solely by inadequate performance evidence does not automatically establish De Novo eligibility.
Regulatory consequences of the decisions
A substantial equivalence determination permits marketing subject to applicable requirements. A granted De Novo request establishes the new type’s risk classification and a classification regulation, potentially affecting future devices as well as the applicant’s product.
The De Novo device may subsequently serve as a predicate under appropriate conditions. A substantial-equivalence pathway may thus become available in an area previously lacking a predicate. Each later device’s intended use and technology still require assessment.
Why does incorrect pathway selection matter?
Innovation alone is not a proper basis for selecting De Novo. Attempting 510(k) without an appropriate predicate may likewise create problems. Existing classifications, intended use, and technology should be reviewed together.
FDA classification information and prior decisions help develop strategy. Presubmission feedback may clarify technical and regulatory uncertainties where necessary.
The essential distinction is assessment through substantial equivalence to a predicate versus risk-based classification as a new device type. Correct selection helps manufacturers structure evidence and compliance work around the relevant requirements.
How is risk assessed for new devices?
Risk assessment is fundamental to selecting a regulatory category and identifying safety and effectiveness requirements in De Novo. The FDA considers intended use, potential effects on patients, and available controls alongside technology. New device types are classified under appropriate controls using scientific evidence.
The purpose is to identify foreseeable hazards and determine whether they can be adequately controlled. Low- or moderate-risk status must therefore rely on valid evidence supporting device characteristics and controls, rather than manufacturer statements alone.
Intended use and patient safety
Intended use should first be clearly defined, including the healthcare need and clinical conditions. Devices using similar technologies may present different risks when used for different purposes.
A device displaying health data may differ in risk from one directly informing clinical decisions. Users, environment, interpretation, and misuse consequences should be examined together. Effects on patients and users matter alongside technical function.
Identifying potential hazards
Manufacturers should systematically identify foreseeable risks during intended use. Analysis covers adverse situations arising from design, operation, user interaction, or insufficient performance.
It should extend beyond physical failures to incorrect outputs, use errors, clinical decision effects, and failure to perform as intended, as applicable.
- Performance risks: Harm from inaccurate or inconsistent performance.
- Use risks: Misuse or incorrect interpretation.
- Technological risks: Functional problems involving software, hardware, or other components.
- Clinical risks: Adverse effects on diagnosis, monitoring, or treatment decisions.
- Information deficiencies: Inadequate instructions, warnings, or explanation of limitations.
Assessing control adequacy
Identifying risks alone is insufficient. Manufacturers must explain mitigation and why controls are adequate. Controls may involve design, performance validation, instructions, and applicable special regulatory requirements.
The FDA considers whether controls provide reasonable assurance. General controls may support Class I, while additional special controls may support Class II. Classification therefore depends on required controls as well as the existence of risks.
How does benefit-risk balance affect the decision?
Assessment considers expected health benefits and adverse consequences together, including benefit characteristics, risk severity and probability, and evidence adequacy. It examines whether probable benefits outweigh probable risks with the proposed controls.
Innovative devices may involve uncertainty. The FDA considers its nature and significance. Innovation or unmet clinical need does not remove evidence requirements; the assessment should be supported by data relevant to intended use.
What scientific evidence is used?
Evidence varies by technology, intended use, and risks. Bench assessments, performance testing, software validation, usability studies, and clinical investigations may be relevant. The same evidence set is not mandatory for every device.
Data should meaningfully support safety, effectiveness, and identified risks. Manufacturers should explain which risks tests address, which controls they validate, and how remaining uncertainties are managed.
Effects on the regulatory submission
Accurate risk assessment is central to eligibility. De Novo may be unsuitable where general and special controls cannot provide sufficient assurance, requiring another pathway.
A granted request establishes the device type’s class and controls, influencing both the applicant’s market entry and future assessments. Evidence, intended use, and applicable controls therefore form the foundation of De Novo classification.
Why does the absence of an equivalent product matter?
The absence of an existing equivalent is a key consideration in selecting a De Novo pathway. The FDA examines intended use, technological characteristics, and legally marketed predicates. No appropriate predicate may mean that conventional 510(k) substantial equivalence is unavailable.
However, no similar marketed product does not automatically establish eligibility. The device must be low or moderate risk, with suitable controls providing reasonable assurance. Predicate research is therefore a systematic regulatory and evidence assessment, beyond a commercial comparison.
Why is the legal predicate concept decisive?
A predicate is an appropriate legally marketed U.S. device against which substantial equivalence can be assessed. Devices must share intended use and permit an appropriate comparison of technological characteristics.
Commercially similar functions do not necessarily establish a valid predicate. Regulatory status, intended use, and technology should be examined together to avoid selection based only on appearance or function.
Technological innovation versus regulatory equivalence
Different components, advanced software, or original design do not necessarily prevent equivalence. Differences may be acceptable where they raise no different safety or effectiveness questions and adequate evidence is available.
Different questions or intended use may instead affect suitability for 510(k). Manufacturers should examine innovation’s effect on existing classifications rather than focus on novelty alone.
What should equivalent-product research examine?
Existing classifications and legally marketed devices should be reviewed systematically. This establishes predicate availability and explains the new product’s differences.
- Intended use: Compare new and existing uses.
- Technology: Assess operational and functional differences affecting safety and effectiveness.
- Classification: Examine established types and decisions.
- Legal marketing status: Verify predicate suitability.
- Risk differences: Identify new safety or effectiveness questions.
- Evidence: Determine independent evidence needs where comparison is unavailable.
How does no predicate affect De Novo?
Manufacturers may submit directly after determining that no suitable predicate exists. A prior 510(k) is not always necessary. Applicants should explain why existing devices are unsuitable and why a new type is justified.
The FDA examines intended use, benefits, risks, and controls. No predicate does not remove evidence requirements; safe and effective use under suitable controls must still be justified.
Devices found not substantially equivalent
A 510(k) may receive a Not Substantially Equivalent (NSE) determination. De Novo may be considered following decisions involving no suitable predicate, new intended use, or technology raising different questions.
Insufficient performance data alone is not an adequate justification. Evidence gaps should be distinguished from the need for a new classification, and strategy should reflect the FDA’s stated reasons.
Long-term effects of classification
A granted request establishes an appropriate classification for a previously unclassified new type. It affects both the applicant’s market entry and future similar products.
The classified device may become a predicate for later 510(k)s. Predicate absence is therefore an important starting condition, while final eligibility depends on risk, evidence, and controls.
What classification outcomes result from a De Novo decision?
Completion determines an innovative device’s regulatory position. The FDA assesses scientific evidence, intended use, benefits, and foreseeable risks. A grant identifies the new type within the system and establishes applicable controls.
The request may be granted or denied. Granted types are classified as Class I or II according to required controls. The decision authorizes the applicant’s device and establishes a classification regulation for future similar devices.
Effects on Class I and Class II
Class I may apply where general controls provide assurance; Class II may apply where special controls are additionally required. This determines subsequent obligations.
Special controls may involve performance requirements, tests, labeling, or other measures supporting risk management. Classification establishes the regulatory approach to the type’s risks.
Establishing a classification regulation
A grant creates a regulation defining the type, class, and controls. This establishes a framework for technology previously lacking a suitable predicate.
The FDA publishes decisions and related information officially. Manufacturers should review the resulting classification and control provisions, beyond the submission outcome alone.
What follows a granted request?
A grant has several consequences for the device and its type. Correct interpretation helps manufacturers identify postmarket responsibilities.
- Marketing authorization: The device may be marketed subject to applicable requirements.
- Class: The type becomes Class I or II.
- Regulation: Its definition and controls are established.
- Special controls: These may be established for Class II types.
- Future submissions: The device may serve as a predicate under appropriate conditions.
- Postmarket obligations: Applicable requirements must be fulfilled.
Does De Novo mean FDA approval?
A De Novo classification differs from Premarket Approval (PMA). A grant authorizes marketing through classification under relevant conditions. PMA is a separate scientific and regulatory pathway, particularly for Class III devices.
Calling a De Novo grant PMA approval is technically incorrect. Manufacturers should use clearance, De Novo authorization, and PMA approval according to the nature of the official decision.
What happens if the request is denied?
The FDA may deny a request if evidence is insufficient, controls cannot provide reasonable assurance, or probable benefits do not outweigh probable risks. Class I or II classification then does not occur.
The device remains Class III and cannot be legally marketed on the denied request alone. The FDA provides written reasons. Manufacturers may develop further evidence, submit a new request, or consider PMA where appropriate.
Effects on subsequent 510(k)s
The newly classified device may become a legal predicate for future products. A technology initially assessed without a comparator may subsequently support 510(k).
This does not authorize every later device automatically. Intended use, technology, necessary comparisons, special controls, and other obligations still require assessment.
Effects on manufacturers’ strategies
A grant requires postmarket planning. Classification and controls may determine quality management, documentation, labeling, and monitoring requirements.
The decision should be reviewed with its scope, intended use, and applicable requirements. It is a comprehensive classification outcome defining class, controls, and a potential foundation for future devices, rather than merely permission to enter the market.
Common errors when selecting the submission pathway
Correct pathway selection is fundamental for innovative device manufacturers. The FDA considers intended use, technology, existing classifications, and safety and effectiveness requirements. Inadequate review may lead to unsuitable submissions and additional requirements.
De Novo applies to new types without predicates for which appropriate controls provide reasonable assurance. Comparing De Novo, 510(k), and PMA by innovation alone is inappropriate. Strategy should reflect regulatory position and risk.
Assuming every innovative device qualifies
New software, design, or advanced functions do not automatically mean that no predicate exists.
510(k) may remain possible where intended use is the same and technological differences raise no new questions. Existing classifications and predicates should therefore be researched first.
Insufficient predicate research
Commercial catalogs and comparisons of similar features may be inadequate. The proposed predicate’s lawful marketing status and intended use must be examined.
No identical commercial function alone does not justify De Novo. Classification records, marketing decisions, and product categories should be reviewed to determine necessity.
Key assessment errors in strategy
Errors often arise from unclear intended use or failure to link risk with classification. Manufacturers should systematically examine decision points before submission.
- Unclear intended use: Insufficient clinical purpose makes classification difficult.
- Innovation as the sole criterion: New technology does not establish eligibility.
- Incomplete predicate research: Insufficient review may lead to the wrong pathway.
- Inadequate risk assessment: Unclear hazards and controls may undermine review.
- Disconnected evidence: Data may fail to support safety, effectiveness, or proposed controls.
- Overlooked format: Failure to meet current electronic and content requirements may affect acceptance review.
Misinterpreting an NSE decision
Not every NSE determination supports De Novo equally. No predicate, new intended use, or technology raising different questions may be relevant.
Failure solely due to insufficient performance evidence does not prove a new category. Manufacturers should distinguish evidence gaps from classification needs using the FDA’s reasons.
Incorrect risk classification
High-risk devices for which general and special controls are insufficient do not qualify merely because they are innovative.
Intended use, harms, users, and controls should be assessed together. Control adequacy requires evidence; otherwise, the request may be denied and other requirements apply.
Not using presubmission feedback
Where classification is uncertain, the Pre-Submission process may provide feedback on specific technical or regulatory questions, including pathway or evidence strategy.
Feedback does not grant marketing authorization or guarantee De Novo. It should inform strategy while necessary evidence is prepared, helping address uncertainties earlier.
Overlooking current electronic requirements
Scientific content alone is insufficient. Format and electronic requirements also apply. Since October 1, 2025, nonexempt De Novo requests must use eSTAR unless a waiver applies.
eSTAR structures required information and documents. Missing mandatory fields or overlooking requirements may create acceptance-review problems. Current submission methods should therefore inform strategy.
A systematic selection approach
Intended use, classification, predicates, and controls should be assessed together to choose between De Novo, 510(k), and PMA. This also identifies evidence needed during development.
Comprehensive early review reduces inappropriate selections. Correct De Novo use depends on a justified strategy based on risks, predicates, and controls rather than innovation alone.
The effect of a De Novo decision on subsequent devices
A grant does more than authorize the applicant’s device. It establishes classification for a new type previously lacking a suitable predicate, creating a starting point for future assessments.
A Class I or II De Novo device may serve as a predicate for later 510(k)s under appropriate conditions. However, the new classification does not automatically authorize every device in the field.
Creating a new device type
A grant establishes a regulation defining the type, class, and controls. Previously uncategorized products gain a defined assessment framework.
This helps manufacturers understand development requirements. Intended use, risks, and controls provide important references for future submissions.
Can De Novo devices serve as 510(k) predicates?
Yes, where relevant conditions are met. Later manufacturers may compare their devices with the legally marketed De Novo device to establish equivalence.
The same intended use and appropriate technological assessment remain necessary. Different safety or effectiveness questions may prevent equivalence. No automatic clearance follows from the earlier decision.
What should later manufacturers assess?
The classification provides valuable strategy information, but each new product requires its own assessment. Reliance on the prior decision alone is insufficient.
- Intended use: Compare the new device and predicate.
- Technology: Assess operational and technological differences.
- Controls: Review general and special requirements.
- Equivalence: Support comparisons with evidence where 510(k) is required.
- Performance: Determine necessary validation.
- Postmarket duties: Assess applicable responsibilities.
How do special controls affect later devices?
Class II De Novo types may receive device-specific special controls. Their content depends on technology, intended use, and assessed safety and effectiveness issues.
Later manufacturers should review these requirements, which may address performance, labeling, or other mitigation measures. The framework influences later conformity work as well as the first assessment.
Does a grant make later submissions easier?
It may enable 510(k) comparison using an established predicate and reduce some uncertainty. The effect is not identical for every device.
A classification may include a 510(k) exemption, or a later product may not be equivalent because of use or technology. Current classification and obligations must be examined.
Public information on De Novo decisions
The FDA provides granted classification information through official databases and publications, including names, classes, decisions, and frameworks. Decision summaries may explain scientific and regulatory reasoning.
These sources support research but do not disclose another manufacturer’s entire file. Trade secrets and confidential information remain protected. New applicants remain responsible for their own evidence.
Postmarket responsibilities
A grant does not end obligations. Quality management, labeling, registration and listing, adverse-event reporting, and other duties may apply according to classification and legislation.
Later manufacturers must likewise meet their own requirements. Another device’s authorization does not permit independent marketing without the required regulatory assessment.
Long-term regulatory significance
De Novo integrates innovative devices into the regulatory system with appropriate controls. The classification may guide future development and requirements for similar intended uses.
Manufacturers should treat decisions as regulatory information influencing later development and assessment. De Novo can establish predicates for future 510(k)s under appropriate conditions and support risk-based regulation.

